drugset / Trial / NCT04028388
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for treatment with a taxane.
Timeline
- Start
- 2019-07-17
- Primary completion
- 2021-11-29
- Completion
- 2021-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 20 mg | Intravenous |
| Comparator | Docetaxel | Small molecule | 30 mg | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |
| Background | Ritonavir | Other / unclassified | 200 mg | Oral |